Luisa Klotz

10.5k total citations · 1 hit paper
162 papers, 4.9k citations indexed

About

Luisa Klotz is a scholar working on Pathology and Forensic Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Luisa Klotz has authored 162 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pathology and Forensic Medicine, 58 papers in Immunology and 40 papers in Molecular Biology. Recurrent topics in Luisa Klotz's work include Multiple Sclerosis Research Studies (65 papers), Neuroinflammation and Neurodegeneration Mechanisms (28 papers) and Immunotherapy and Immune Responses (22 papers). Luisa Klotz is often cited by papers focused on Multiple Sclerosis Research Studies (65 papers), Neuroinflammation and Neurodegeneration Mechanisms (28 papers) and Immunotherapy and Immune Responses (22 papers). Luisa Klotz collaborates with scholars based in Germany, United States and Switzerland. Luisa Klotz's co-authors include Heinz Wiendl, Sven G. Meuth, Catharina C. Groß, Thomas Klockgether, Stephanie Hucke, Reinhard Hohlfeld, Percy A. Knolle, Tanja Kuhlmann, Nicholas Schwab and Andreas Schulte‐Mecklenbeck and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Luisa Klotz

151 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice

2017 650 citations Kerstin Berer, Lisa Ann Gerdes et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Luisa Klotz

Since Specialization

Citations

This map shows the geographic impact of Luisa Klotz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luisa Klotz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luisa Klotz more than expected).

Fields of papers citing papers by Luisa Klotz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luisa Klotz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luisa Klotz. The network helps show where Luisa Klotz may publish in the future.

Co-authorship network of co-authors of Luisa Klotz

This figure shows the co-authorship network connecting the top 25 collaborators of Luisa Klotz. A scholar is included among the top collaborators of Luisa Klotz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luisa Klotz. Luisa Klotz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis 2025 ·Neurological Research and Practice ·Franz Felix Konen, Torsten Witte, Diana Ernst, David Hagin, Konstantin Fritz Jendretzky, Nora Möhn, Sandra Nay, Lea Grote‐Levi, Kurt‐Wolfram Sühs, Luisa Klotz, Steffen Pfeuffer, Refik Pul, Christoph Kleinschnitz, (unknown), (unknown), Thomas Skripuletz	0
2	Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook 2025 ·Therapeutic Advances in Neurological Disorders ·Luisa Klotz, Thomas Berger, Wallace Brownlee, (unknown), Jan Lycke, Celia Oreja‐Guevara, Filipe Palavra, Francesco Saccà, Tobias Sejbæk, Martin S. Weber, Gavin Giovannoni	1
3	Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab 2025 ·Multiple Sclerosis Journal ·(unknown), (unknown), Maria Eveslage, (unknown), (unknown), Andreas Schulte‐Mecklenbeck, Catharina C. Groß, Jan D. Lünemann, (unknown), Catharina Korsukewitz, Heinz Wiendl, Luisa Klotz	0
4	Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis 2025 ·Neurology Neuroimmunology & Neuroinflammation ·Jesper Dahl, (unknown), Christopher Winter, (unknown), Veit Rothhammer, (unknown), Anne‐Katrin Pröbstel, Tradite Neziraj, (unknown), Johanna Oechtering, Jens Kühle, (unknown), (unknown), (unknown), Luisa Klotz, (unknown), Stefanie Küerten	4
5	Ravulizumab and Efgartigimod in Myasthenia Gravis 2024 ·Neurology Neuroimmunology & Neuroinflammation ·Frauke Stascheit, (unknown), Annette Aigner, (unknown), Christian W. Keller, Luisa Klotz, Sophie Lehnerer, (unknown), (unknown), (unknown), Lea Gerischer, Sarah Hoffmann, Konstantinos Lazaridis, John Tzartos, Heinz Wiendl, Andreas Meisel, Jan D. Lünemann	5
6	Inflammation in multiple sclerosis: consequences for remyelination and disease progression 2023 ·Nature Reviews Neurology ·Luisa Klotz, Jack P. Antel, Tanja Kuhlmann	64
7	Neutrophils—biology and diversity 2023 ·Nephrology Dialysis Transplantation ·Daniela Begandt, (unknown), Luisa Klotz, Luise Erpenbeck, Jadwiga Jabłońska, Roland Immler, Anja Hasenberg, (unknown), Andrea Herrero-Cervera, (unknown), (unknown), Alexander Zarbock, Sven Brandau, Christian Schulz, Oliver Soehnlein, Stefanie Steiger	10
8	Implications of immunometabolism for smouldering MS pathology and therapy 2023 ·Nature Reviews Neurology ·Stefan Bittner, Katrin Pape, Luisa Klotz, Frauke Zipp	5
9	Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis 2022 ·Multiple Sclerosis and Related Disorders ·Imtiaz A. Samjoo, Luisa Klotz, Gavin Giovannoni, (unknown), (unknown), Evelyn Worthington, Melody Zhao, (unknown), Dieter A. Häring, Chris Cameron, Nicholas Adlard	10
10	Complement Activation Is a Prominent Feature of MOGAD 2021 ·Annals of Neurology ·Christian W. Keller, Joseph A. Lopez, Eva‐Maria Wendel, Sudarshini Ramanathan, Catharina C. Groß, Luisa Klotz, Markus Reindl, Russell C. Dale, Heinz Wiendl, Kevin Rostásy, Fabienne Brilot, Jan D. Lünemann	35
11	Efficacy classification of modern therapies in multiple sclerosis 2021 ·Journal of Comparative Effectiveness Research ·Imtiaz A. Samjoo, Evelyn Worthington, (unknown), Melody Zhao, Chris Cameron, Dieter A. Häring, (unknown), Luisa Klotz, Nicholas Adlard	80
12	Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab 2021 ·Journal of Neurology Neurosurgery & Psychiatry ·Steffen Pfeuffer, Tobias Ruck, Refik Pul, Leoni Rolfes, Catharina Korsukewitz, Marc Pawlitzki, Brigitte Wildemann, Luisa Klotz, Christoph Kleinschnitz, Antonio Scalfari, Heinz Wiendl, Sven G. Meuth	20
13	Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA 2020 ·JMIR Research Protocols ·Tjalf Ziemssen, Olaf Hoffmann, Luisa Klotz, Herbert Schreiber, Martin S. Weber, (unknown)	16
14	Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis 2020 ·Journal of Comparative Effectiveness Research ·Imtiaz A. Samjoo, Evelyn Worthington, (unknown), Melody Zhao, Chris Cameron, Dieter A. Häring, (unknown), Luisa Klotz, Nicholas Adlard	45
15	Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice breakdown → 2017 ·Proceedings of the National Academy of Sciences ·Kerstin Berer, Lisa Ann Gerdes, Egle Cekanaviciute, Xiaoming Jia, Liang Xiao, Zhongkui Xia, Chuan Liu, Luisa Klotz, (unknown), Sergio E. Baranzini, Tania Kümpfel, Reinhard Hohlfeld, Gurumoorthy Krishnamoorthy, Hartmut Wekerle	650
16	Teri-DYNAMIC: Exploring the impact of teriflunomide on immune cell population size, receptor repertoire, and function in patients with RRMS 2017 ·Document Server@UHasselt (UHasselt) ·Heinz Wiendl, Catharina C. Groß, Melanie Eschborn, (unknown), (unknown), (unknown), Vincent Van Pesch, (unknown), Sandrine Brette, Timothy J. Turner, Amit Bar‐Or, Luisa Klotz	0
17	Increased Antigen Cross-Presentation but Impaired Cross-Priming after Activation of Peroxisome Proliferator-Activated Receptor γ Is Mediated by Up-Regulation of B7H1 2009 ·The Journal of Immunology ·Luisa Klotz, Stephanie Hucke, Dominik Thimm, Sabine Claßen, (unknown), Joachim L. Schultze, Frank Edenhofer, Christian Kurts, Thomas Klockgether, Andreas Limmer, Percy A. Knolle, Sven Burgdorf	32
18	Peroxisome Proliferator-Activated Receptor γ Control of Dendritic Cell Function Contributes to Development of CD4+ T Cell Anergy 2007 ·The Journal of Immunology ·Luisa Klotz, Indra Dani, Frank Edenhofer, Lars Nolden, Bernd O. Evert, (unknown), Waldemar Kolanus, Thomas Klockgether, Percy A. Knolle, Linda Diehl	103
19	Proinflammatory Stimulation and Pioglitazone Treatment Regulate Peroxisome Proliferator-Activated Receptor γ Levels in Peripheral Blood Mononuclear Cells from Healthy Controls and Multiple Sclerosis Patients 2005 ·The Journal of Immunology ·Luisa Klotz, Mathias V. Schmidt, Thomas Giese, Magdalena Sastre, Percy A. Knolle, Thomas Klockgether, Michael T. Heneka	96
20	Hepatocellular Alterations after Intraportal Transplantation of Ovarian Tissue in Ovariectomized Rats 2000 ·American Journal Of Pathology ·Luisa Klotz, Hans Jörg Hacker, Dietrich Klingmüller, Peter Bannasch, U. Pfeifer, Frank Dombrowski	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact